Expression of immunophenotype, inflammatory response and chromosomal abnormality in acute lymphoid leukemia
Author affiliations
DOI:
https://doi.org/10.15625/vjbt-24015Keywords:
Acute lymphoblastic leukemia, BCR-ABL, malignant lymphoid cells, TGF-β.Abstract
Acute lymphoblastic leukemia (ALL) is the most common childhood malignant hematologic disease characterized by the uncontrolled accumulation of lymphoid progenitor cells within the bone marrow and peripheral blood. According to the World Health Organization (WHO) classification and National Comprehensive Cancer Network (NCCN) guidelines, ALL patients are classified into two main risk groups, including standard-risk and poor-risk groups based on clinical and biological features, including age at diagnosis, white blood cell count, cytogenetic abnormalities, and early treatment response. Inflammation-related genes, such as tumor necrosis factor-α (TNFα)-induced protein 3 (TNFAIP3, A20), tumor suppressor cylindromatosis (CYLD) and Cezanne genes, are negative regulators of immune cell activation, and cell survival. To this end, 57 patients diagnosed with ALL and 30 healthy subjects were enrolled. Immunophenotype was determined by flow cytometry, gene expression and chromosomal abnormalities by quantitative PCR, and secretion of cytokines by ELISA. As a result, the poor-risk group had age-related higher levels of lactate dehydrogenase (LDH), white blood cell, lymphocytes and neutrophil counts than the standard-risk group. Cytokine analysis revealed that transforming growth factor beta (TGF-β) levels were markedly increased in the poor-risk group. In addition, expression levels of CYLD, A20, and Cezanne genes were not significantly different between the two groups, although CYLD levels tended to be lower in the poor-risk group. Importantly, p210 BCR-ABL and p190 BCR-ABL fusion transcripts were detected more frequently in poor-risk patients. In conclusion, this study indicates that age-related numbers of malignant lymphoid cells, but not inflammatory expression, were associated with poor outcomes in ALL patients.
Downloads
References
Adnan-Awad S., Kim D., Hohtari H., Javarappa K. K., Brandstoetter T., Mayer I., et al. (2021). Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets. Leukemia, 35(7), 1964–1975. https://doi.org/10.1038/s41375-020-01082-4
Amarante-Mendes G. P., Rana A., Datoguia T. S., and Hamerschlak N. (2022). BCR-ABL1 tyrosine kinase complex signaling transduction: Challenges to overcome resistance in chronic myeloid leukemia. International Journal of Molecular Sciences, 14(1), https://doi.org/10.3390/pharmaceutics14010215
Arber D. A., Orazi A., Hasserjian R., Thiele J., Borowitz M. J., Le Beau M. M., et al. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127(20), 2391–2405. https://doi.org/10.1182/blood-2016-06-721662
Bakhtiyari M., Liaghat M., Aziziyan F., Shapourian H., Yahyazadeh S., Alipour M., et al. (2023). The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways. Cell Communication and Signaling, 21(1), 252. https://doi.org/10.1186/s12964-023-01282-2
Balkwill F. (2009). Tumour necrosis factor and cancer. Nature Reviews Cancer, 9(5), 361–371. https://doi.org/10.1038/nrc2628
Baccarani M., Rosti G., and Soverini S. (2019). Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type. Leukemia, 33(10), 2358–2364. https://doi.org/10.1038/s41375-019-0562-1
Brown P. A., Shah B., Advani A., Aoun P., Boyer M. W., Burke P. W., et al. (2021). Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 19(9), 1079–1109. https://doi.org/10.6004/jnccn.2021.0042
Brück O., Dufva O., Hohtari H., Blom S., Turkki R., Ilander M., et al. (2020). Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival. Blood Advances, 4(2), 274–286. https://doi.org/10.1182/bloodadvances.2019000792
Chao M. P., Alizadeh A. A., Tang C., Jan M., Weissman-Tsukamoto R., Zhao F., et al. (2011). Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Research, 71(4), 1374–1384. https://doi.org/10.1158/0008-5472.CAN-10-2238
Collison L. W., Delgoffe G. M., Guy C. S., Vignali K. M., Chaturvedi V., Fairweather D., et al. (2012). The composition and signaling of the IL-35 receptor are unconventional. Nature Immunology, 13(3), 290–299. https://doi.org/10.1038/ni.2227
De Wilde K., Martens A., Lambrecht S., Jacques P., Drennan M. B., Debusschere K., et al. (2017). A20 inhibition of STAT1 expression in myeloid cells: a novel endogenous regulatory mechanism preventing development of enthesitis. Annals of the Rheumatic Diseases, 76(3), 585–592. https://doi.org/10.1136/annrheumdis-2016-209454
Donadieu J., Auclerc M. F., Baruchel A., Perel Y., Bordigoni P., Landman-Parker J., et al. (2000). Prognostic study of continuous variables (white blood cell count, peripheral blast cell count, haemoglobin level, platelet count and age) in childhood acute lymphoblastic leukaemia. Analysis of a population of 1545 children treated by the French Acute Lymphoblastic Leukaemia Group (FRALLE). British Journal of Cancer, 83(12), 1617–1622. https://doi.org/10.1054/bjoc.2000.1504
Espinosa L., Cathelin S., D’Altri T., Trimarchi T., Statnikov A., Guiu J., et al. (2010). The Notch/Hes1 pathway sustains NF-kappaB activation through CYLD repression in T cell leukemia. Cancer Cell, 18(3), 268–281. https://doi.org/10.1016/j.ccr.2010.08.006
Farkas T., Müller J., Erdélyi D. J., Csóka M., and Kovács G. T. (2017). Absolute lymphocyte count (alc) after induction treatment predicts survival of pediatric patients with acute lymphoblastic leukemia. Pathology and Oncology Research, 23(4), 889–897. https://doi.org/10.1007/s12253-017-0192-8
Fizzotti M., Chen E. Y., Link M. P., Carroll A. J., Foroni L., Rabbitts T. H., et al. (1994). Simultaneous expression of RBTN-2 and BCR-ABL oncogenes in a T-ALL with t(11;14) (p13;q11) and a late-appearing Philadelphia chromosome. Leukemia, 8(7), 1124–1130.
Gu Y., Wu S., Fan J., Meng Z., Gao G., Liu T., et al. (2024). CYLD regulates cell ferroptosis through Hippo/YAP signaling in prostate cancer progression. Cell Death and Disease, 15(1), 79. https://doi.org/10.1038/s41419-024-06464-5
Ha L. T., Giang N. H., Toan N. L., Giang N. V., Mao C. V., Nhat N. Q., et al. (2025). Cross-sectional study: Associations of A20 and Cezanne with leukocyte accumulation in B-cell acute lymphoblastic leukemia. Medicina (Kaunas), 61(7). https://doi.org/10.3390/medicina61071166
Hafiz M. G., and Mannan M. A. (2007). Serum lactate dehydrogenase level in childhood acute lymphoblastic leukemia. Bangladesh Medical Research Council Bulletin, 33(3), 88–91. https://doi.org/10.3329/bmrcb.v33i3.1139
Hu X., and Ivashkiv L. B. (2009). Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity, 31(4), 539–550. https://doi.org/10.1016/j.immuni.2009.09.002
Hunter C. A., and Jones S. A. (2015). IL-6 as a keystone cytokine in health and disease. Nature Immunology, 16(5), 448–457. https://doi.org/10.1038/ni.3153
Huyen N. T., Ngoc N. T., Giang N. H., Trang D. T., Hanh H. H., Binh V. D., et al. (2023). CYLD stimulates macrophage phagocytosis of leukemic cells through STAT1 signalling in acute myeloid leukemia. PLoS One, 18(8), e0283586. https://doi.org/10.1371/journal.pone.0283586
Jedlička M., Feglarová T., Janstová L., Hortová-Kohoutková M., and Frič J. (2022). Lactate from the tumor microenvironment - A key obstacle in NK cell-based immunotherapies. Frontiers in Immunology, 13, 932055. https://doi.org/10.3389/fimmu.2022.932055
Junmei Z., Fengkuan Y., Yongping S., Baijun F., Yuzhang L., Lina L., et al. (2015). Coexistence of P190 and P210 BCR/ABL transcripts in chronic myeloid leukemia blast crisis resistant to imatinib. SpringerPlus, 9(4), 170. https://doi.org/10.1186/s40064-015-0930-x
Kantarjian H., and Jabbour E. (2025). Adult acute lymphoblastic leukemia: 2025 update on diagnosis, therapy, and monitoring. American Journal of Hematology, 100(7), 1205–1231. https://doi.org/10.1002/ajh.27708
Li M. O., Wan Y. Y., Sanjabi S., Robertson A. K., and Flavell R. A. (2006). Transforming growth factor-beta regulation of immune responses. Annual Review of Immunology, 24, 99–146. https://doi.org/10.1146/annurev.immunol.24.021605.090737
Lin H. K., Bergmann S., and Pandolfi P. P. (2005). Deregulated TGF-beta signaling in leukemogenesis. Oncogene, 24(37), 5693–5700. https://doi.org/10.1038/sj.onc.1208923
Livak K. J., and Schmittgen T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods (San Diego, Calif.), 25(4), 402–408. https://doi.org/10.1006/meth.2001.1262
Meyer S. C., and Levine R. L. (2014). Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. Clinical Cancer Research, 20(8), 2051–2059. https://doi.org/10.1158/1078-0432.CCR-13-0279
Modi H., McDonald T., Chu S., Yee J. K., Forman S. J., and Bhatia R. (2007). Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells. Blood, 109(12), 5411–5421. https://doi.org/10.1182/blood-2006-06-032490
Mosher N., Torkildson J., Golden C., Raphael R., Beach B., Michlitsch J., et al. (2022). Utilization of thiopurine metabolites and allopurinol in pediatric acute lymphoblastic leukemia: Consideration for an algorithmic approach. Journal of Pediatric Hematology/ Oncology, 44(2), e521–e525. https://doi.org/10.1097/MPH.0000000000002313
Naji N. S., Sathish M., and Karantanos T. (2024). Inflammation and related signaling pathways in acute myeloid leukemia. Cancers (Basel), 16(23). https://doi.org/10.3390/cancers16233974
Panigrahi M., Swain T. R., Jena R. K., and Panigrahi A. (2016). L-asparaginase-induced abnormality in plasma glucose level in patients of acute lymphoblastic leukemia admitted to a tertiary care hospital of Odisha. Indian Journal of Pharmacology, 48(5), 595–598. https://doi.org/10.4103/0253-7613.190762
Park K. M., Yang E. J., Lee J. M., Hah J. O., Park S. K., Park E. S., et al. (2020). Treatment outcome in pediatric acute lymphoblastic leukemia with hyperleukocytosis in the Yeungnam region of Korea: A multicenter retrospective study. Journal of Pediatric Hematology/Oncology, 42(4), 275–280. https://doi.org/10.1097/MPH.0000000000001771
Primo D., Flores J., Quijano S., Sanchez M. L., Sarasquete M. E., del Pino-Montes J., et al. (2006). Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia. British Journal of Haematology, 135(1), 43–51. https://doi.org/10.1111/j.1365-2141.2006.06265.x
Pui C. H., and Jeha S. (2007). New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nature Reviews Drug Discovery, 6(2), 149–165. https://doi.org/10.1038/nrd2240
Radwan R. E., El-Kholy W. M., Elsaed A., and Darwish A. (2024). Genetic predisposition meets cytokine imbalance: The influence of TNF-α (−308) polymorphism and TGF-β levels in pediatric acute lymphoblastic leukemia in Egypt. BMC Cancer, 24(1), 1509. https://doi.org/10.1186/s12885-024-13224-3
Rego E. M., Tone L. G., Garcia A. B., and Falcao R. P. (1999). CD10 and CD19 fluorescence intensity of B-cell precursors in normal and leukemic bone marrow. Clinical characterization of CD10(+strong) and CD10(+weak) common acute lymphoblastic leukemia. Leukemia Research, 23(5), 441–450. https://doi.org/10.1016/s0145-2126(98)00190-8
Ren R. (2005). Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nature Reviews Cancer, 5(3), 172–183. https://doi.org/10.1038/nrc1567
Schober S., Rottenberger J. M., Hilz J., Schmid E., Ebinger M., Feuchtinger T., et al. (2023). Th1 cytokines in pediatric acute lymphoblastic leukemia. Cancer Immunology, Immunotherapy, 72(11), 3621–3634. https://doi.org/10.1007/s00262-023-03512-5
Shah B., Mattison R. J., Abboud R., Abdelmessieh P., Aldoss I., Burke P. W., et al. (2024). Acute lymphoblastic leukemia, version 2.2024, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 22(8), 563–576. https://doi.org/10.6004/jnccn.2024.0051
Shi X., Yang J., Deng S., Xu H., Wu D., Zeng Q., et al. (2022). TGF-β signaling in the tumor metabolic microenvironment and targeted therapies. Journal of Hematology and Oncology, 15(1), 135. https://doi.org/10.1186/s13045-022-01349-6
Xu X., Kalac M., Markson M., Chan M., Brody J. D., Bhagat G., et al. (2020). Reversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia/lymphoma (ATLL). Cell Death Discovery, 11(2), 94. https://doi.org/10.1038/s41419-020-2294-6
Ye H., Adane B., Khan N., Alexeev E., Nusbacher N., Minhajuddin M., et al. (2018). Subversion of systemic glucose metabolism as a mechanism to support the growth of leukemia cells. Cancer Cell, 34(4), 659–673.e6. https://doi.org/10.1016/j.ccell.2018.08.016
Yu T., Zhan Q., Yan X., Luo X., Wang X., Tang X., et al. (2023). Clinical significance of WT1 in the evaluation of therapeutic effect and prognosis of non-M3 acute myeloid leukemia. Cancer Biology and Therapy, 24(1), 2285801. https://doi.org/10.1080/15384047.2023.2285801
Wiemels J. (2012). Perspectives on the causes of childhood leukemia. Chemico-Biological Interactions, 196(3), 59–67. https://doi.org/10.1016/j.cbi.2012.01.007
Downloads
Published
How to Cite
Issue
Section
